Codexis/CDXS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Codexis

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Ticker

CDXS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Stephen Dilly

Employees

174

Headquarters

Redwood city, United States

Codexis Metrics

BasicAdvanced
$238M
Market cap
-
P/E ratio
-$0.94
EPS
2.10
Beta
-
Dividend rate
$238M
2.10411
$4.91
$1.45
480K
3.712
3.628
35.452
35.452
-35.43%
-63.45%
-43.38%
3.213
3.008
3.105
-36.13%
-29.21%
0.52%

What the Analysts think about Codexis

Analyst Ratings

Majority rating from 8 analysts.
Buy

Codexis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-67.64% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$17M
-35.85%
Net income
-$12M
61.97%
Profit margin
-67.64%
152.48%

Codexis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.17
-$0.50
-$0.10
-$0.16
-
Expected
-$0.21
-$0.32
-$0.12
-$0.18
-$0.26
Surprise
-20.47%
54.18%
-19.54%
-11.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Codexis stock?

Codexis (CDXS) has a market cap of $238M as of June 18, 2024.

What is the P/E ratio for Codexis stock?

The price to earnings (P/E) ratio for Codexis (CDXS) stock is 0 as of June 18, 2024.

Does Codexis stock pay dividends?

No, Codexis (CDXS) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next Codexis dividend payment date?

Codexis (CDXS) stock does not pay dividends to its shareholders.

What is the beta indicator for Codexis?

Codexis (CDXS) has a beta rating of 2.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Codexis stock price target?

The target price for Codexis (CDXS) stock is $7.13, which is NaN% below the current price of $. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Codexis stock

Buy or sell Codexis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing